News summary

The Results of Phase III OptiTROP-Lung06 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ESMO Oral Presentation and Simultaneously Published in The New England Journal of Medicine

Source: PR Newswire • Published: 25 Oct 2026, 10:37

Summarized by Masters of Longevity from PR Newswire.

Sac-TMT plus pembrolizumab delayed progression in selected advanced lung cancer patients. Overall survival remains preliminary.

The Results of Phase III OptiTROP-Lung06 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ESMO Oral Presentation and Simultaneously Published in The New England Journal of Medicine
Key Takeaways
  • The trial enrolled PD-L1-negative patients without EGFR or ALK mutations.
  • Median progression-free survival was 15.0 months versus 5.7 months.
  • An overall survival benefit has not yet been established.
Read the full article at PR Newswire ↗

Continue exploring

Recommended MoL Picks

MoL PickCreatine and Cancer: Why New Mouse Studies Point in Opposite DirectionsCreatine strengthened antitumour immune cells in one mouse study—and promoted metastasis through platelets in another. The apparent contradiction reveals why neither result is a supplement recommendation.MoL PickGrowth Hormone Receptor Deletion Extends Mouse LifespanStudy summary: researchers switched off the growth hormone receptor in middle-aged mice and followed survival and physical function.MoL PickPlan Your Health Tests in Three MinutesThe free Personal Health Diagnostics Planner turns a short questionnaire into a ranked, personalised PDF: a clearer starting point for deciding which health checks deserve attention now.